Delhi High Court Demands Government Response on Illegal Online Diagnostic Services Amid Public Health Concerns

Spread the Message

Read Time:4 Minute, 3 Second

The Delhi High Court has directed the Union Health Ministry to file a reply by January 20, 2026, on a contempt petition challenging online diagnostic services like Amazon Diagnostics for operating without required registrations under Indian law. Pathologist and RTI activist Dr. Rohit Jain filed the petition, alleging these platforms violate the Clinical Establishments (Registration and Regulation) Act, 2010, by offering home sample collection and digital reports without proper clinical establishment status. This development revives a 2020 court order mandating action against such aggregators, highlighting ongoing regulatory gaps in India’s booming digital health sector.

Regulatory Framework at Stake

The Clinical Establishments Act, 2010, mandates registration for entities providing diagnostic services, defining clinical establishments as facilities offering diagnosis, treatment, or care for illness, including labs and clinics. It requires minimum standards for facilities, qualified personnel, record-keeping, and compliance with medico-legal norms, but applies directly only in select states and Union Territories—not fully in Delhi, though courts have invoked it for enforcement. Online aggregators like Amazon Diagnostics, launched in June 2025 with partner Orange Health Labs, facilitate home collections across 450+ PIN codes including Delhi, but the petition argues e-commerce platforms cannot qualify as registered establishments.

Dr. Rohit Jain, a pathologist with 17 years of experience advocating for lab regulations, emphasized in prior statements that unregulated services lead to inaccurate reports from pre-analytical errors, like improper sample handling by untrained collectors, affecting India’s 1.4 billion population. The petition names the Health Ministry, Delhi government, Director General of Health Services, and ICMR for “wilful disobedience” of court directives.

Historical Context and Prior Directives

This contempt plea stems from a 2020 Public Interest Litigation where the Delhi High Court ordered action against illegal online health aggregators amid COVID-19 testing concerns. In 2021, the Union Health Ministry notified states to crack down on platforms failing to disclose lab registrations, staff qualifications, or compliance, terming it a “grave concern” for citizen safety, as signed by then-Secretary Rajesh Bhushan. A 2023 government assurance promised strict enforcement, yet the petition claims inaction persists.

Similar challenges have arisen nationally; for instance, the Supreme Court in 2017 ruled only pathologists with postgraduate qualifications can authorize reports, but enforcement lags. During the pandemic, platforms like 1mg and Healthian faced scrutiny for unaccredited COVID tests.

The Booming Online Diagnostics Market

India’s diagnostics market reached USD 35.4 billion in 2024, with home services valued at USD 221.38 million and projected to hit USD 328.51 million by 2031 at a 5.80% CAGR, driven by urban convenience and chronic disease rise. Amazon’s service, available in Delhi, Bengaluru, Mumbai, and Hyderabad, exemplifies this via app-based bookings, home phlebotomy, and e-reports—appealing for privacy and no-travel benefits, especially post-COVID.

Proponents highlight reduced infection risks, time savings, and access for elderly or remote users, with certified partners claiming NABL-accredited labs. However, limitations include scope restricted to blood/urine tests, excluding imaging.

Expert Perspectives and Risks

Experts warn of significant dangers. Dr. Jain notes quackery in diagnostics causes fraud via fake signatures and poor quality controls, with unregulated collectors risking sample integrity. Dr. Prasad Kulkarni, another pathologist, has questioned aggregator legitimacy via RTIs, echoing concerns over revenue-sharing without medical oversight.

Internationally, home tests risk self-misdiagnosis, but India’s issues amplify due to weak enforcement; benefits like monitoring evaporate if reports err. A balanced view: regulated platforms could enhance access, but current gaps invite “grave risk to public health.”

Public Health Implications

Unregulated services could erode trust in diagnostics, delaying accurate care for conditions like diabetes or cancer, prevalent in India. For consumers, this means verifying lab accreditations (e.g., NABL, ICMR-approved) before booking; practical tip: cross-check reports with qualified pathologists. Broader impacts include pushing for national sample transport policies and digital signature guidelines, as ordered in related 2024-2025 cases.

If enforced, shutdowns might curb growth but safeguard standards; inaction risks more petitions. Diverse views: industry seeks guidelines for compliance, while activists demand bans until regulated.

Potential Limitations and Counterpoints

The Act’s patchy implementation—effective in only some regions—complicates nationwide enforcement. Platforms argue partnerships with registered labs suffice, though petitions counter aggregators bear liability. No response from Amazon yet, but market growth suggests consumer demand for convenience outweighs risks for some. Counterarguments include innovation stifling, yet evidence prioritizes safety.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.